ATM and prostate cancer: Here we show that AtmKD also compromises HR, a pathway implicated in breast, ovarian, pancreatic and prostate cancers, in which recurrent ATM missense mutations were recently identified (Roberts et al., 2012; Cremona and Behrens, 2014).